- Results delivered in an average of seven days… 해외 바카라 사이트 speed shortened by two weeks compared to NGS
- 해외 바카라 사이트 results were unveiled at the European Society of Genetics in Milan, Italy
[by Ji, Yong Jun] Gencurix, a company specializing in cancer molecular diagnostics, announced on May 23 that its endometrial cancer diagnostic product, the ‘Droplex POLE Mutation Test,’ demonstrated diagnostic accuracy and rapid turnaround time in clinical trials conducted at hospitals affiliated with the United Kingdom’s National Health Service (NHS).
The clinical 해외 바카라 사이트 was jointly conducted by Sheffield Children’s Hospital and Leeds St. James’s University Hospital in the UK. The findings from the study will be presented in poster format at the European Society of Human Genetics (ESHG 2025) conference, scheduled to take place in Milan, Italy, on May 24.
The clinical trial results showed that Gencurix’s Droplex POLE 해외 바카라 사이트 Test delivered results in an average of seven days, with the fastest turnaround in just four days, approximately two weeks faster than conventional next-generation sequencing (NGS) methods. In addition, the company explained that the test demonstrated 100% accuracy and sensitivity and maintained high reproducibility even with low-concentration DNA samples, thereby confirming its reliability for diagnostic use.
The ‘POLE gene’ 해외 바카라 사이트 is an important biomarker for predicting the prognosis of endometrial cancer patients. Patients who test positive for the 해외 바카라 사이트s are classified as low-risk (POLEmut) and may be able to avoid unnecessary chemotherapy. Conversely, patients without the 해외 바카라 사이트 can proceed with early precision testing and transition to active treatment. Therefore, the speed and accuracy of diagnosis are essential components in implementing an effective personalized treatment strategy.
The World Health Organization (WHO), the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the International Federation of Gynecology and Obstetrics (FIGO) all recommend POLE gene 해외 바카라 사이트 testing for the diagnosis and personalized treatment of endometrial cancer patients.
Gencurix’s POLE 해외 바카라 사이트 test is the world’s first commercialized diagnostic product utilizing digital PCR technology. In March 2024, it was designated by the Ministry of Health and Welfare as a target for the ‘New Medical Technology Evaluation Delay’ program. The test has since received in vitro diagnostic certification (CE-IVD) in Europe and regulatory approval from the Ministry of Food and Drug Safety in Korea. Leveraging this, Gencurix is currently providing testing services to approximately 30 general hospitals in Korea and exporting the diagnostic product to countries in Europe and Asia.
“These clinical results are an example demonstrating not only the diagnostic accuracy of the Droplex POLE 해외 바카라 사이트 test, but also its clinical utility and market competitiveness,” stated Jeong Jong-seok, head of the Global Business Division at Gencurix. “We plan to further solidify our position as a global leader in the field of cancer precision diagnostics,” he added.